Metabolic Syndrome XNCT06877130
Effect of Blood Flow Restriction on Cardiovascular Function in Elderly with Metabolic Syndrome X
A study testing Aerobic exercise with BFR and Aerobic training in people with Metabolic Syndrome X and Cardiovascular Problems in Elderly, run by Cairo University at 1 site in Egypt.
Trial summary
The purpose of the study is to investigate the effect of aerobic exercise with Blood flow restriction training (BFR) on cardiovascular function and quality of life in hypertensive elderly patients. Read more about this study
- Who is it for?
- Ages 60 to 70 years
- Conditions the study is for
- Metabolic Syndrome X, Cardiovascular Problems in Elderly
- What is being tested?
- Aerobic exercise with BFR and Aerobic training
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2024to 10 Feb 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- sixty elderly patients.
- Their ages will range from 60 to 70 years old.
- Grade II Hypertensive patients (SBP 160-179 mmHg and/or DBP 100-109 mmHg)
- Patients with dyslipidemia: at least one of the fasting lipid profile tests include the following results.
- A-Total Cholestrol more than 240 (mg/dl). B-LDL Cholestrol more than 160 (mg/dl). C-HDL Cholestrol less than 40 (mg/dl). D-Triglycerides more than 200 (mg/dl).
- 'Body Mass Index: from 30: 40 kg/m2 calss I and II obesity.
Who cannot join
- Severe Chest diseases (either obstructive or restrictive).
- Clinical signs of a severe cardiac event. (eg, severe atherosclerosis, congestive heart failure),
- Severe psychiatric or cognitive impairment, who unable to follow comment.
- Neurological disorders affecting respiratory muscles or any muscular dystrophies (cervical disc or bulge).
- Patients with severe self-limiting illness (e.g., cancer).
- Peripheral artery disease in lower extremities.
- Systolic blood pressure < 180 mmHg, diastolic blood pressure more than 110 mmHg, or resting heart rate above 120 bpm.
- Patient with uncontrolled - diabetes.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Faculty of Physical Therapy, Cairo University
Giza, Giza Governorate, 11432
About this study
The purpose of the study is to investigate the effect of aerobic exercise with Blood flow restriction training (BFR) on cardiovascular function and quality of life in hypertensive elderly patients.
Hypothesis There will be no significant effect of aerobic exercise with RBF on cardiovascular function and the quality of life in hypertensive elderly patients.
Read the detailed description
Sixty elderly patients with metabolic syndrome X aged from 65 to 75 years old. will be selected from Al-Ahrar teaching hospital -zagazig governorate.
Study Design:
This experimental comparative control study will be performed after patients' clinical assessment who will be randomly allocated into two equal groups:
Group A (aerobic exercise with BFR group):
Thirty patients will apply moderate aerobic exercise with RBF in form of a treadmill for 30 minutes for 12 weeks (3 sessions/ week).
Group B (aerobic training group):
Thirty patients will apply moderate intensity aerobic exercise without BFR for 30 minutes for 12 weeks (3 sessions/ weak).
Equipment:
A- Evaluative Equipment:
- Weight and height scale: (ZT-120 model, health scale made in china).
- Sphygmomanometer: (Model Number: GT001-110/111 aneroid sphygmomanometer, Zhejiang, China)
- Pulse oximeter: (Pulse Oximeter GRANZIA Model No: AS-304).
- Lab investigation: using blood sample to test the following factors A- Lipid Profile: Cobas Integra 400 Plus- Switzerland. B- Apolipoprotien: Cobas Integra 400 plus -Switzerland.
- Functional assessment: A-Timed Up and Go (TUG) Test The Timed Up and Go (TUG) test is a reliable, cost-effective, safe, and time-efficient way to evaluate overall functional mobility. B- Fatigue Assessment Scale (FAS): it is a way of measuring physical activity intensity level.
- Quality of life assessment by using HeartQoL questionnaire
- Treatment Equipment:
- Treadmill, (Model Grand Fit Ac 8885- china)
- BFR Training Therapy Occlusion Air Cuffs.
III) Procedures:
A- Evaluating Procedure:
History will be carefully taken to collect data about his general condition, physical therapy, and current medication.
The procedure of this study will be divided into the following main parts:
Preparatory procedure:
- All medical and demographic data of subjects will be collected. B. Vital signs will be measured to ensure that all subjects are medically stable.
- Recording data sheet: All data and information of each patient who participated in this study including name, age, address, weight, and height were recorded in the recording datasheet.
- Weight and height: A valid and reliable universal height and weight scale is used to determine the subjects' height and weight. Before treatment, each patient's height- and -weight were calculated to determine their body's mass index (BMI) using the following equation: BMI=weight (Kgs) /height (m2)
- Blood pressure monitoring by (Aneroid Sphygmomanometers) Aneroid sphygmomanometers were used to obtain a BP reading.
- Pulse rate by Pulse oximeter: It is widely used to noninvasively assess arterial oxyhemoglobin saturation (SpO2) and rate of heart (HR) during rest and activity.
- Lipid profile: All patients will perform laboratory lipid profile before and after the study. The three main blood levels collected to assess for dyslipidemia is (TG, HDL-C, LDL-C and T.G) after fasting for 8-12 hours. (Rosenson et al.2021).
- apolipoprotien test: test to detect the risk of cardiovascular disease
- Functioal assessment A-time up and go test: A sturdy armchair with a back was placed at the end of a hallway adjacent to where height and weight measures are routinely taken in the process of rooming participants. A piece of tape was placed on the floor 3 m away from the front edge of the chair. Patients were seated in the chair with back against the chair back, arms resting on the armrests, and given general instructions about the task, including walking at a normal rather than a rapid speed. The TUG required patients to stand up out of the chair, walk 3 m, turn around, walk back to the chair, and sit down. Patients were given the following instructions: "stand up on the word 'go,' walk to the tape, turn around, walk back to the chair, and sit down." The timing of the test began at the word "go," and ended when the participant was seated. B- Fatigue Assessment Scale (FAS) The FAS is a 10-item scale evaluating symptoms of chronic fatigue. In contrast to other similar measures the FAS treats fatigue as a unidimensional construct and does not separate its measurement into different factors. However, in order to ensure that the scale would evaluate all aspects of fatigue, developers chose items to represent both physical and mental symptoms. Each item of the FAS is answered using a five-point scale ranging from 1 ("never") to 5 ("always"). Items 4 and 10 are reverse scored. Total scores can range from 10, indicating the lowest level of fatigue, to 50, denoting the highest.
- HeartQoL questionnaire. According to European Journal of Preventive Cardiology 2016 HeartQoL is a recently developed core health-related quality of life instrument for patients with coronary heart disease. The current study aims to investigate its association with patients' coronary risk profile and to provide reference values for patients with coronary heart disease (Appendix II).
- The double product (DP): consisting of the SBP multiplied by the pulse rate (PR), is an index of myocardial oxygen consumption.
- Mean Arterial Pressure:
The definition of mean arterial pressure (MAP) is the average arterial pressure throughout one cardiac cycle, systole, and diastole. MAP is influenced by cardiac output and systemic vascular resistance, each of which is influenced by several variables. (DeMers D et al 2023).
A common method used to estimate the MAP is the following formula:
- MAP = DP + 1/3(SP - DP)
- Therapeutic procedure:
- Aerobic exercise training
- Target heart rate: Maximum Heart Rate Formula: HR max = 206.9 - (0.67 x age) (Jackson et al., 2007). Moderate intensity aerobic exercise: the rate of heart reaches 64-76 percent of their age predicted peak hearty rate (American College of Sports Medicine et al. 2018).
- Determination of BFR To prescribe BFR training, Systolic blood pressure (SBP) will be measured using an automated oscillometer BP device
Blood pressure will be measured according to the recommendations of the American Heart Association. A bilateral restriction of 50% of the measured SBP will be applied to each lower limb for the application of BFR of lower limbs using the equipment. A wide cuff (18 cm wide) will be placed in the proximal portion of the thigh (inguinal fold region) and will be inflated until the absence of the tibial artery blood pulse. Thus, a 50% restriction of SBP will be applied in both legs during lower body exercises.
- Being tested
- Aerobic exercise with BFR, Aerobic training
- Keywords
- Metabolic Syndrome X, Blood Flow Restriction (BFR) Training Effects, Cardiovascular Functions in Elderly
- Medical subject headings
- Metabolic Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Aerobic exercise with BFROther
To prescribe BFR training, Systolic blood pressure (SBP) will be measured using an automated oscillometer BP device.
Blood pressure will be measured according to the recommendations of the American Heart Association. A bilateral restriction of 50% of the measured SBP will be applied to each lower limb for the application of BFR of lower limbs using the equipment. A wide cuff (18 cm wide) will be placed in the proximal portion of the thigh (inguinal fold region) and will be inflated until the absence of the tibial artery blood pulse. Thus, a 50% restriction of SBP will be applied in both legs during lower body exercises.
Aerobic trainingOther
HR max = 206.9 - (0.67 x age).
Moderate intensity aerobic exercise: the rate of heart reaches 64-76 percent of their age predicted peak hearty rate
| Study group | Role | What they receive |
|---|---|---|
| Group A (aerobic exercise with BFR group) | Experimental | Thirty patients will apply moderate aerobic exercise with RBF in form of a treadmill for 30 minutes for 12 weeks (3 sessions/ week). Receives: Other: Aerobic exercise with BFR; Other: Aerobic training |
| Group B (aerobic training group) | Active comparator | Thirty patients will apply moderate intensity aerobic exercise without BFR for 30 minutes for 12 weeks (3 sessions/ weak). Receives: Other: Aerobic training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Weight and height measurement
Weight and height are recorded, and BMI will be calculated according to the formula: BMI = Weight (Kg) / Height (m2)
Measured: Baseline (assessment).
Blood pressure monitoring by (Aneroid Sphygmomanometers)
Aneroid sphygmomanometers were used to obtain a BP reading (Pickering TG et al., 2005). Virtually 100% of the values. From the aneroid-device were within the three-mm-Hg range recommended' by the Association for the Advancement of Medical instrumentation.
Measured: Baseline (assessment), and at 12 weeks post-intervention.
Pulse rate by Pulse oximeter
It is widely used to noninvasively assess arterial oxyhemoglobin saturation (SpO2).
Measured: Baseline (assessment), and at 12 weeks post-intervention.
Lipid profile
All patients will perform laboratory lipid profile before and after the study. The three main blood levels collected to assess for dyslipidemia is (TG, HDL-C, LDL-C and T.G) after fasting for 8-12 hours.
Measured: Baseline (assessment), and at 12 weeks post-intervention.
apolipoprotien test
: test to detect the risk of cardiovascular disease
Measured: Baseline (assessment), and at 12 weeks post-intervention.
time up and go test
A sturdy armchair with a back was placed at the end of a hallway adjacent to where height and weight measures are routinely taken in the process of rooming participants.
A piece of tape was placed on the floor 3 m away from the front edge of the chair. Patients were seated in the chair with back against the chair back, arms resting on the armrests, and given general instructions about the task, including walking at a normal rather than a rapid speed.
The TUG required patients to stand up out of the chair, walk 3 m, turn around, walk back to the chair, and sit down. Patients were given the following instructions: "stand up on the word 'go,' walk to the tape, turn around, walk back to the chair, and sit down." The timing of the test began at the word "go," and ended when the participant was seated
Measured: Baseline (assessment), and at 12 weeks post-intervention.
Fatigue Assessment Scale
The FAS is a 10-item scale evaluating symptoms of chronic fatigue. In contrast to other similar measures the FAS treats fatigue as a unidimensional construct and does not separate its measurement into different factors. However, in order to ensure that the scale would evaluate all aspects of fatigue, developers chose items to represent both physical and mental symptoms.
Each item of the FAS is answered using a five-point scale ranging from 1 ("never") to 5 ("always"). Items 4 and 10 are reverse scored. Total scores can range from 10, indicating the lowest level of fatigue, to 50, denoting the highest.
Measured: Baseline (assessment), and at 12 weeks post-intervention.
HeartQoL questionnaire
According to European Journal of Preventive Cardiology 2016 HeartQoL is a recently developed core health-related quality of life instrument for patients with coronary heart disease. The current study aims to investigate its association with patients' coronary risk profile and to provide reference values for patients with coronary heart disease
Measured: Baseline (assessment), and at 12 weeks post-intervention.
The double product (DP)
consisting of the SBP multiplied by the pulse rate (PR), is an index of myocardial oxygen consumption
Measured: Baseline (assessment), and at 12 weeks post-intervention.
Mean Arterial Pressure
The definition of mean arterial pressure (MAP) is the average arterial pressure throughout one cardiac cycle, systole, and diastole. MAP is influenced by cardiac output and systemic vascular resistance, each of which is influenced by several variables.
A common method used to estimate the MAP is the following formula:
MAP = DP + 1/3(SP - DP)
Measured: Baseline (assessment), and at 12 weeks post-intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2025
- Study start1 Jan 2024
- Primary completion1 Dec 2024
- Study completion10 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metabolic Syndrome XStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Karim Mohsen Abdeltawaab, Cairo University
- Investigators
- Zeinab Mohamed Helmy, Professor of Physical Therapy, Study chair, Professor of Physical Therapy for Cardiovascular / Respiratory Disorders and Geriatrics Faculty of Physical Therapy Cairo UniversityEbtesam Nabil Abdel Mohsen, Lecturer of Physical Therapy, Study director, Lecturer of Physical Therapy for Cardiovascular / Respiratory Disorders and Geriatrics Faculty of Physical Therapy Cairo UniversityYasser Abdel Monem Elhendy, Professor of Internal Medicine, Study director, Professor of Internal Medicine Faculty of Medicine Zagazig University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06877130
- Sponsor's protocol ID
- P.T.REC/012/005597
- Status last verified
- Mar 2025
- First submitted
- 2 Mar 2025
- Last updated
- 14 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Blood Flow Restriction on Cardiovascular Function in Elderly with Metabolic Syndrome X
- ClinicalTrials.gov ID
- NCT06877130
- Acronym / sponsor ID
- P.T.REC/012/005597
- Keywords
- Metabolic Syndrome X, Blood Flow Restriction (BFR) Training Effects, Cardiovascular Functions in Elderly
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 1 Dec 2024 (actual)
- Study completion
- 10 Feb 2025 (actual)
- First posted
- 14 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to investigate the effect of aerobic exercise with Blood flow restriction training (BFR) on cardiovascular function and quality of life in hypertensive elderly patients.
Hypothesis There will be no significant effect of aerobic exercise with RBF on cardiovascular function and the quality of life in hypertensive elderly patients.
Detailed description
Sixty elderly patients with metabolic syndrome X aged from 65 to 75 years old. will be selected from Al-Ahrar teaching hospital -zagazig governorate.
Study Design:
This experimental comparative control study will be performed after patients' clinical assessment who will be randomly allocated into two equal groups:
Group A (aerobic exercise with BFR group):
Thirty patients will apply moderate aerobic exercise with RBF in form of a treadmill for 30 minutes for 12 weeks (3 sessions/ week).
Group B (aerobic training group):
Thirty patients will apply moderate intensity aerobic exercise without BFR for 30 minutes for 12 weeks (3 sessions/ weak).
Equipment:
A- Evaluative Equipment:
- Weight and height scale: (ZT-120 model, health scale made in china).
- Sphygmomanometer: (Model Number: GT001-110/111 aneroid sphygmomanometer, Zhejiang, China)
- Pulse oximeter: (Pulse Oximeter GRANZIA Model No: AS-304).
- Lab investigation: using blood sample to test the following factors A- Lipid Profile: Cobas Integra 400 Plus- Switzerland. B- Apolipoprotien: Cobas Integra 400 plus -Switzerland.
- Functional assessment: A-Timed Up and Go (TUG) Test The Timed Up and Go (TUG) test is a reliable, cost-effective, safe, and time-efficient way to evaluate overall functional mobility. B- Fatigue Assessment Scale (FAS): it is a way of measuring physical activity intensity level.
- Quality of life assessment by using HeartQoL questionnaire
- Treatment Equipment:
- Treadmill, (Model Grand Fit Ac 8885- china)
- BFR Training Therapy Occlusion Air Cuffs.
III) Procedures:
A- Evaluating Procedure:
History will be carefully taken to collect data about his general condition, physical therapy, and current medication.
The procedure of this study will be divided into the following main parts:
Preparatory procedure:
- All medical and demographic data of subjects will be collected. B. Vital signs will be measured to ensure that all subjects are medically stable.
- Recording data sheet: All data and information of each patient who participated in this study including name, age, address, weight, and height were recorded in the recording datasheet.
- Weight and height: A valid and reliable universal height and weight scale is used to determine the subjects' height and weight. Before treatment, each patient's height- and -weight were calculated to determine their body's mass index (BMI) using the following equation: BMI=weight (Kgs) /height (m2)
- Blood pressure monitoring by (Aneroid Sphygmomanometers) Aneroid sphygmomanometers were used to obtain a BP reading.
- Pulse rate by Pulse oximeter: It is widely used to noninvasively assess arterial oxyhemoglobin saturation (SpO2) and rate of heart (HR) during rest and activity.
- Lipid profile: All patients will perform laboratory lipid profile before and after the study. The three main blood levels collected to assess for dyslipidemia is (TG, HDL-C, LDL-C and T.G) after fasting for 8-12 hours. (Rosenson et al.2021).
- apolipoprotien test: test to detect the risk of cardiovascular disease
- Functioal assessment A-time up and go test: A sturdy armchair with a back was placed at the end of a hallway adjacent to where height and weight measures are routinely taken in the process of rooming participants. A piece of tape was placed on the floor 3 m away from the front edge of the chair. Patients were seated in the chair with back against the chair back, arms resting on the armrests, and given general instructions about the task, including walking at a normal rather than a rapid speed. The TUG required patients to stand up out of the chair, walk 3 m, turn around, walk back to the chair, and sit down. Patients were given the following instructions: "stand up on the word 'go,' walk to the tape, turn around, walk back to the chair, and sit down." The timing of the test began at the word "go," and ended when the participant was seated. B- Fatigue Assessment Scale (FAS) The FAS is a 10-item scale evaluating symptoms of chronic fatigue. In contrast to other similar measures the FAS treats fatigue as a unidimensional construct and does not separate its measurement into different factors. However, in order to ensure that the scale would evaluate all aspects of fatigue, developers chose items to represent both physical and mental symptoms. Each item of the FAS is answered using a five-point scale ranging from 1 ("never") to 5 ("always"). Items 4 and 10 are reverse scored. Total scores can range from 10, indicating the lowest level of fatigue, to 50, denoting the highest.
- HeartQoL questionnaire. According to European Journal of Preventive Cardiology 2016 HeartQoL is a recently developed core health-related quality of life instrument for patients with coronary heart disease. The current study aims to investigate its association with patients' coronary risk profile and to provide reference values for patients with coronary heart disease (Appendix II).
- The double product (DP): consisting of the SBP multiplied by the pulse rate (PR), is an index of myocardial oxygen consumption.
- Mean Arterial Pressure:
The definition of mean arterial pressure (MAP) is the average arterial pressure throughout one cardiac cycle, systole, and diastole. MAP is influenced by cardiac output and systemic vascular resistance, each of which is influenced by several variables. (DeMers D et al 2023).
A common method used to estimate the MAP is the following formula:
- MAP = DP + 1/3(SP - DP)
- Therapeutic procedure:
- Aerobic exercise training
- Target heart rate: Maximum Heart Rate Formula: HR max = 206.9 - (0.67 x age) (Jackson et al., 2007). Moderate intensity aerobic exercise: the rate of heart reaches 64-76 percent of their age predicted peak hearty rate (American College of Sports Medicine et al. 2018).
- Determination of BFR To prescribe BFR training, Systolic blood pressure (SBP) will be measured using an automated oscillometer BP device
Blood pressure will be measured according to the recommendations of the American Heart Association. A bilateral restriction of 50% of the measured SBP will be applied to each lower limb for the application of BFR of lower limbs using the equipment. A wide cuff (18 cm wide) will be placed in the proximal portion of the thigh (inguinal fold region) and will be inflated until the absence of the tibial artery blood pulse. Thus, a 50% restriction of SBP will be applied in both legs during lower body exercises.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A (aerobic exercise with BFR group) | Experimental | Other: Aerobic exercise with BFR, Other: Aerobic trainingThirty patients will apply moderate aerobic exercise with RBF in form of a treadmill for 30 minutes for 12 weeks (3 sessions/ week). |
| Group B (aerobic training group) | Active comparator | Other: Aerobic trainingThirty patients will apply moderate intensity aerobic exercise without BFR for 30 minutes for 12 weeks (3 sessions/ weak). |
Who may qualify
- Ages
- 60 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- sixty elderly patients.
- Their ages will range from 60 to 70 years old.
- Grade II Hypertensive patients (SBP 160-179 mmHg and/or DBP 100-109 mmHg)
- Patients with dyslipidemia: at least one of the fasting lipid profile tests include the following results.
- A-Total Cholestrol more than 240 (mg/dl). B-LDL Cholestrol more than 160 (mg/dl). C-HDL Cholestrol less than 40 (mg/dl). D-Triglycerides more than 200 (mg/dl).
Key exclusion criteria (8 listed)
- Severe Chest diseases (either obstructive or restrictive).
- Clinical signs of a severe cardiac event. (eg, severe atherosclerosis, congestive heart failure),
- Severe psychiatric or cognitive impairment, who unable to follow comment.
- Neurological disorders affecting respiratory muscles or any muscular dystrophies (cervical disc or bulge).
- Patients with severe self-limiting illness (e.g., cancer).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Aerobic exercise with BFRTo prescribe BFR training, Systolic blood pressure (SBP) will be measured using an automated oscillometer BP device. Blood pressure will be measured according to the recommendations of the American Heart Association. A bilateral restriction of 50% of the measured SBP will be applied to each lower limb for the application of BFR of lower limbs using the equipment. A wide cuff (18 cm wide) will be placed in the proximal portion of the thigh (inguinal fold region) and will be inflated until the absence of the tibial artery blood pulse. Thus, a 50% restriction of SBP will be applied in both legs during lower body exercises. | Other | Group A (aerobic exercise with BFR group) |
| Aerobic trainingHR max = 206.9 - (0.67 x age). Moderate intensity aerobic exercise: the rate of heart reaches 64-76 percent of their age predicted peak hearty rate | Other | Group A (aerobic exercise with BFR group), Group B (aerobic training group) |
Primary outcome
Weight and height measurement
Time frame: Baseline (assessment).
Weight and height are recorded, and BMI will be calculated according to the formula: BMI = Weight (Kg) / Height (m2)
Blood pressure monitoring by (Aneroid Sphygmomanometers)
Time frame: Baseline (assessment), and at 12 weeks post-intervention.
Aneroid sphygmomanometers were used to obtain a BP reading (Pickering TG et al., 2005). Virtually 100% of the values. From the aneroid-device were within the three-mm-Hg range recommended' by the Association for the Advancement of Medical instrumentation.
Pulse rate by Pulse oximeter
Time frame: Baseline (assessment), and at 12 weeks post-intervention.
It is widely used to noninvasively assess arterial oxyhemoglobin saturation (SpO2).
Lipid profile
Time frame: Baseline (assessment), and at 12 weeks post-intervention.
All patients will perform laboratory lipid profile before and after the study. The three main blood levels collected to assess for dyslipidemia is (TG, HDL-C, LDL-C and T.G) after fasting for 8-12 hours.
apolipoprotien test
Time frame: Baseline (assessment), and at 12 weeks post-intervention.
: test to detect the risk of cardiovascular disease
time up and go test
Time frame: Baseline (assessment), and at 12 weeks post-intervention.
A sturdy armchair with a back was placed at the end of a hallway adjacent to where height and weight measures are routinely taken in the process of rooming participants. A piece of tape was placed on the floor 3 m away from the front edge of the chair. Patients were seated in the chair with back against the chair back, arms resting on the armrests, and given general instructions about the task, including walking at a normal rather than a rapid speed. The TUG required patients to stand up out of the chair, walk 3 m, turn around, walk back to the chair, and sit down. Patients were given the following instructions: "stand up on the word 'go,' walk to the tape, turn around, walk back to the chair, and sit down." The timing of the test began at the word "go," and ended when the participant was seated
Fatigue Assessment Scale
Time frame: Baseline (assessment), and at 12 weeks post-intervention.
The FAS is a 10-item scale evaluating symptoms of chronic fatigue. In contrast to other similar measures the FAS treats fatigue as a unidimensional construct and does not separate its measurement into different factors. However, in order to ensure that the scale would evaluate all aspects of fatigue, developers chose items to represent both physical and mental symptoms. Each item of the FAS is answered using a five-point scale ranging from 1 ("never") to 5 ("always"). Items 4 and 10 are reverse scored. Total scores can range from 10, indicating the lowest level of fatigue, to 50, denoting the highest.
HeartQoL questionnaire
Time frame: Baseline (assessment), and at 12 weeks post-intervention.
According to European Journal of Preventive Cardiology 2016 HeartQoL is a recently developed core health-related quality of life instrument for patients with coronary heart disease. The current study aims to investigate its association with patients' coronary risk profile and to provide reference values for patients with coronary heart disease
The double product (DP)
Time frame: Baseline (assessment), and at 12 weeks post-intervention.
consisting of the SBP multiplied by the pulse rate (PR), is an index of myocardial oxygen consumption
Mean Arterial Pressure
Time frame: Baseline (assessment), and at 12 weeks post-intervention.
The definition of mean arterial pressure (MAP) is the average arterial pressure throughout one cardiac cycle, systole, and diastole. MAP is influenced by cardiac output and systemic vascular resistance, each of which is influenced by several variables. A common method used to estimate the MAP is the following formula: MAP = DP + 1/3(SP - DP)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Mar 2025.
- Individual participant dataSharing planned: No
Related trials for Metabolic Syndrome X
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
RecruitingObservational study
Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
Cushing Disease
RecruitingObservational study
Cancer in Inherited Bone Marrow Failure Syndromes
Diamond Blackfan Anemia, Dyskeratosis Congenita
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Active, not recruiting
Insulin Resistance and Coronary Microvascular Dysfunction in Patients With Myocardial Ischemia and Non-obstructive Coronary Artery Disease
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zeinab Mohamed Helmy, Professor of Physical Therapy study chair
Professor of Physical Therapy for Cardiovascular / Respiratory Disorders and Geriatrics Faculty of Physical Therapy Cairo University
Ebtesam Nabil Abdel Mohsen, Lecturer of Physical Therapy study director
Lecturer of Physical Therapy for Cardiovascular / Respiratory Disorders and Geriatrics Faculty of Physical Therapy Cairo University
Yasser Abdel Monem Elhendy, Professor of Internal Medicine study director
Professor of Internal Medicine Faculty of Medicine Zagazig University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Aerobic exercise with BFR and Aerobic training in people with Metabolic Syndrome X and Cardiovascular Problems in Elderly, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Weight and height measurement (time frame: Baseline (assessment).). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2025.